Back to discover
Disease

Peripheral Arterial Disease

Late-stage therapeutic developmentEmerging researchRising momentum
8
Publications
19
Clinical trials
4
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Epidemiology of peripheral artery disease.

Research2015-04-01Circulation research

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Clopidogrelapproved

Approval — Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patie… (2015)

Evolocumabapproved

Approval — Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary… (2015)

Telmisartanapproved

Approval — Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Red… (2010)

Clinical trials

18 sponsors · 2 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2015emaApprovalEvolocumab· Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Homozygous familial hypercholesterolaemia Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies. Established atherosclerotic cardiovascular disease Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. source ↗
2015emaApprovalClopidogrel· Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. source ↗
2010emaApprovalTelmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage. source ↗
2010emaApprovalTelmisartan· Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or; type 2 diabetes mellitus with documented target organ damage. source ↗
2009emaApprovalClopidogrel· Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome. Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS) Clopidogrel in combination with ASA is indicated in: Adult patients with moderate to high-risk TIA (ABCD2 score ?4) or minor IS (NIHSS ?3) within 24 hours of either the TIA or IS event. Prevention of atherothrombotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. For further information please refer to section 5.1. source ↗
2009emaApprovalClopidogrel· Prevention Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. Prevention of atherothrombotic and thromboembolic events in atrial fibrillation: - In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. source ↗
2009emaApprovalClopidogrel· Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. source ↗
2009emaApprovalClopidogrel· Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

8 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20152023
Most influential
Recent publications
Major themes8
  • Peripheral Arterial Disease2
  • Angioplasty, Balloon, Coronary1
  • Ankle Brachial Index1
  • Global Health1
  • Heart Defects, Congenital1
  • Heart Failure1
  • Lower Extremity1
  • Ocimum basilicum1
Leading journals6
  • Circulation2
  • Circulation research2
  • Cardiovascular therapeutics1
  • European heart journal1
  • Journal of vascular surgery1
  • Lancet (London, England)1
Leading researchers8
  • Aboyans V3
  • Bradbury AW2
  • Criqui MH2
  • Matsushita K2
  • Ricco JB2
  • Aday AW1
  • Bartelink MEL1
  • Bate GR1
Affiliations (unnormalised)6
  • University of California2
  • Advocate Lutheran General Hospital1
  • Baylor College of Medicine1
  • Birmingham Clinical Trials Unit1
  • Center of Thrombosis and Haemostasis1
  • Department of Biomedical and Preclinical Sciences1

Related conditions

4 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Peripheral arterial disease is a disorder of reduced blood flow to the extremities, most often due to atherosclerosis. It is commonly recognized by intermittent claudication and can be identified noninvasively by an ankle-brachial index of 0.9 or less. The literature also emphasizes that asymptomatic disease is more common than symptomatic claudication.

Causes

The supplied grounding identifies atherosclerosis as the cause of peripheral arterial disease. The chronic limb-threatening ischemia guidance also notes that PAD-related limb ischemia is distinct from venous, traumatic, embolic, and nonatherosclerotic causes, which are excluded from that syndrome definition.

Pathophysiology

Peripheral arterial disease reflects impaired perfusion of the lower extremities from atherosclerotic narrowing of the arteries. This reduced blood flow can produce intermittent claudication and, in more severe disease, limb ischemia with rest pain, ulceration, gangrene, and risk of amputation. The literature also links PAD with broader atherosclerotic cardiovascular morbidity and mortality.

Risk factors

Age is a major risk factor, with prevalence and incidence rising sharply in older adults. The supplied abstracts also indicate association with coexisting atherosclerotic disease and cardiovascular morbidity, but they do not provide a fuller risk-factor list.

Current standard of care

Management is described at the level of vascular evaluation and intervention rather than specific drug regimens. For chronic limb-threatening ischemia, the guidance emphasizes urgent referral to a vascular specialist, accurate staging of limb threat, and management that may include surgery. The grounding does not support a more detailed medication-based standard of care for PAD.

AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.